The number of cases of rare blood clots among the millions of people in the UK who have had the Oxford/AstraZeneca vaccine has risen to 168.
The UK’s medicines regulator said the overall case fatality rate was 19%, with 32 deaths up to April 14.
This figure has risen from 22 deaths, up to April 5.
The Medicines and Healthcare products Regulatory Agency (MHRA) said that while the estimated incidence rate of cases has increased over time, the number of cases remains extremely low in the context of the millions of doses administered.
Watch: COVID-19 - Risk of blood clot after coronavirus is eight times higher than after Oxford-AstraZeneca vaccine - study
The regulator’s position remains that the benefits of the AstraZeneca vaccine continue to outweigh the risks for the vast majority of people.
The MHRA said, in its latest weekly summary of Yellow Card reporting, that up to April 14 it had received reports of 168 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in people who had had the AstraZeneca jab.
This is an increase from the figure of 100 case reports up to April 5.
Of the 168 cases in the latest summary, cerebral venous sinus thrombosis (CVST or blood clots in the brain) was reported in 77 cases, and 91 cases had other major thromboembolic events with concurrent thrombocytopenia.
Of the CVST cases, the average age is 47, while for the other major thromboembolic events the average age is 55.
Overall, rare blood clots occurred in 93 women and 75 men aged between 18 and 93.
One case was reported after a second dose of the vaccine, the regulator said.
The estimated number of first doses of the AstraZeneca vaccine given out in the UK by April 14 was 21.2 million, making the overall case incidence 7.9 per million doses, the MHRA said.
This is up from an incidence rate up to April 5 of 4.9 per million doses.
Professor Adam Finn, Professor of Paediatrics at the University of Bristol and a member of the Joint Committee on Vaccination and Immunisation (JCVI), said it is “already clear that it (thrombotic thrombocytopenic syndrome) is going to remain a very rare event”.
He said the reports of more cases is “as expected”.
Prof Finn said: “There is now a very high level of awareness of this syndrome amongst the public and clinicians throughout the country and cases are being reported reliably and quickly but there are also cases that occurred previously now being recognised and reported as well.
“MHRA are using a very clearly defined case definition to ensure consistency. In other words they are making sure that the cases being reported are really this syndrome and not something else.
“This can take some time and while there is uncertainty, unconfirmed cases are designated possible or probable.
“I would expect the true number of cases per million doses of vaccine to become clear fairly soon as these reports stabilise but it is already clear that it is going to remain a very rare event.
“There remains an urgent need to understand the mechanism underlying these cases, to monitor and optimise rapid diagnosis and treatment and, if possible, to identify risk factors all of which might improve outcomes and enable cases to be prevented.”
Watch: What is long COVID?